PCI-32765 (Ibrutinib) in Patients with Newly Diagnosed non-Germinal Center B-Cell subtype of Diffuse Large B-Cell Lymphoma
Study Status
Open to Enrollment
Study Description
This clinical trial is for men and women with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) that is potentially of non-Germinal Center B-Cell (non-GCB) origin.
The study is evaluating the addition of the experimental drug ibrutinib (also known as PCI-32765) to standard chemotherapy to see if it is effective in treating people with non-GCB DLBCL who have not been previously treated.
Study participants will be randomly assigned to one of two treatment arms:
- Arm A: R-CHOP + Ibrutinib
- Arm B: R-CHOP + Placebo (a blank tablet that looks like ibrutinib but contains no medicine)
Disease Status and/or Stage
Newly diagnosed
Sponsor
Janssen
Key Eligibility
- Men and women age 18 and older
- Non-GCB Diffuse Large B-cell Lymphoma (DLBCL)
- No prior treatment for DLCBL
- Detailed eligibility reviewed when you contact the study team
- Rita Gazivoda
- (212) 746-0702
- [email protected]
Principal Investigator
Contact
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Erica Bersin
Tel: (646) 962-8232
[email protected]